Skip to main content
Evidence Snapshot

SGC-7901

CHEMBL614909 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:07Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614909
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats SGC-7901 as ChEMBL target CHEMBL614909. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
SGC-7901
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614909
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why SGC-7901 matters

As of 2026-09-13

SGC-7901 is reviewed as SGC-7901; the current evidence base includes 23 approved drugs, 2236 compounds, and 755 assays, with lead potency reaching pChEMBL 9.5.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 23 approved drugs, 2236 compounds, and 755 assays for this target. The dominant activity type is IC50. CHEMBL58 is the current potency anchor at pChEMBL 9.5.

Use CHEMBL58 as the tractability anchor when discussing potency (pChEMBL 9.5).

Activity source · ChEMBL 36 via Core Engine
23 approved pChEMBL 9.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why SGC-7901 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2236
Total Compounds
755
Total Assays
23
Approved Drugs
IC50: 2159.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL58
 9.5 IC50 Approved
No preferred name
CHEMBL41177
 9.1 IC50 —
No preferred name
CHEMBL28446
 9.0 IC50 —
No preferred name
CHEMBL452936
 8.8 IC50 —
No preferred name
CHEMBL3356793
 8.7 IC50 —

Approved Drugs

Structure Compound First Approval
CRIZOTINIB
CHEMBL601719
 2011
VORINOSTAT
CHEMBL98
 2006
IMATINIB MESYLATE
CHEMBL1642
 2001
TOPOTECAN
CHEMBL84
 1996
DOCETAXEL
CHEMBL3545252
 1995
PACLITAXEL
CHEMBL428647
 1992
PODOFILOX
CHEMBL61
 1990
MITOXANTRONE
CHEMBL58
 1987
ETOPOSIDE
CHEMBL44657
 1983
DOXORUBICIN
CHEMBL53463
 1974
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
 1974
COLCHICINE
CHEMBL107
 1961
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:07Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614909